Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mundipharma Research GmbH & Co KG
ClinicalTrials.gov Identifier:
NCT01112644
First received: April 23, 2010
Last updated: April 9, 2015
Last verified: April 2015